eISSN: 2720-5371
ISSN: 1230-2813
Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
4/2020
vol. 29
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Artykuł oryginalny

Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?

Wojciech Łężak
1
,
Łukasz Mokros
2
,
Jakub M. Kaźmierski
3
,
Dominik Strzelecki
4
,
Hanna Jerczyńska
5
,
Edward Kowalczyk
1
,
Tadeusz Pietras
2, 6

  1. Department of Pharmacology and Toxicology, Medical University of Lodz, Poland
  2. Department of Clinical Pharmacology of the 1st Chair of Internal Diseases, Medical University of Lodz, Poland
  3. Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Poland
  4. Department of Affective and Psychotic Disorders, Medical University of Lodz, Poland
  5. Central Scientific Laboratory (CoreLab), Medical University of Lodz, Poland
  6. Department of Neuroses, Personality Disorders and Eating Disorders, Institute of Psychiatry and Neurology, Warsaw, Poland
Adv Psychiatry Neurol 2020; 29 (4): 205-214
Data publikacji online: 2021/01/30
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Introduction
Physical activity (PA) is considered to be a major preventive factor in psychopharmacotherapy-induced metabolic adverse effects, such as metabolic syndrome induction. The recent discovery of irisin might bring a potential tool with which to supervise patient compliance or create an additional metabolic risk assessment parameter

Material and methods
The sample consisted of 66 in- and out-patients of a Polish hospital. Irisin serum concentrations were measured using commercially available ELISA kits. Sociodemographic and clinical data were obtained from medical records. PA sufficiency was assessed with the use of the International Physical Activity Questionnaire. t-Student, c2 , Fisher’s exact test, Pearson correlation and ANCOVA were used for statistical analysis. The significance level was set at α = 0.05.

Results
The difference in irisin concentrations between patients with sufficient and insufficient PA was not statistically significant. Patients given second generation antipsychotic drugs exhibited lower PA and irisin concentrations than patients on antidepressant drugs or first-generation antipsychotic drugs. Additionally, irisin concentrations were lower in patients with central obesity compared to patients without it.

Conclusions
Irisin does not appear to be a valid, objective tool for the evaluation of patients. However, significant associations between irisin concentrations, psychopharmacotherapy and metabolic parameters were found.

© 2024 Termedia Sp. z o.o.
Developed by Bentus.